Methafluoluothantinib listing application approved for treatment of chronic adult patients with chronic myeloid leukemia
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, it was reported that the listing application for methionate flumartinibinib (product name: Haussen-Fu) was approved for the treatment of chronic myeloid leukemia (Ph-CML) chronic adult patients in Philadelphiamethylene flumartinib is aof theof theNew Drug (http:// which owns China's own intellectual property rights, and has been approved for listing through the priority review and approval processAccording to the National Drug Administration, methicacid fluoratinib is a small molecule protein tyrosine kinase (PTK) inhibitor that induces tumor apoptosis by inhibiting the activity of Bcr-Abl tyrosine kinase, the blood cell proliferation of CML and some acute lymphocytic leukemia patients in Philadelphiathelaunch of methylene fluoromatewillinib will provide new drug options for adult patients with chronic myeloid leukemia in China
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
